Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
Sonali M SmithJames GodfreyKwang Woo AhnAlyssa DiGilioSairah AhmedVaibhav AgrawalVeronika BachanovaUlrike BacherAsad BasheyJavier Bolaños-MeadeMitchell CairoAndy ChenSaurabh ChhabraEdward CopelanParastoo B DahiMahmoud AljurfUmar FarooqSiddhartha GangulyMark HertzbergLeona HolmbergDavid InwardsAbraham S KanateReem KarmaliVaishalee P KenkreMohamed A Kharfan-DabajaAndreas KleinHillard M LazarusMatthew MeiAlberto MussettiTaiga NishihoriPraveen Ramakrishnan GeethakumariAyman SaadBipin P SavaniHarry C SchoutenNirav ShahAlvaro Urbano-IspizuaRavi VijJulie VoseAnna SuredaMehdi HamadaniPublished in: Cancer (2018)
Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. Cancer 2018;124:2541-51. © 2018 American Cancer Society.